Aim: To study the effectiveness and safety of empagliflozin as a preoperative preparation tool, as well as to improve the long-term prognosis of planned percutaneous coronary interventions in patients with type 2 diabetes

Patients with type 2 diabetes will be randomized into 2 groups using the envelope method. One group will receive empagliflozin 10 mg 1 month before planned percutaneous coronary interventions and for 12 months thereafter in addition to previously taken hypoglycemic therapy. Patients of the second group will continue to take previously prescribed hypoglycemic therapy.

Thus, the safety and effectiveness of empagliflozin for preoperative preparation of patients with type 2 diabetes before planned percutaneous coronary interventions will be evaluated, as well as the impact on the immediate and long-term outcomes of percutaneous coronary interventions in comparison with patients on standard hypoglycemic therapy

Inclusion Criteria:

• signed inform concent
• stable coronary artery disease
• planned percutaneous coronary intervention
• diabetes mellitus

Exclusion Criteria:

• previously performed coronary revascularization
• glomerular filtration rate less than 45 ml/min
• intolerance to empagliflozin
• serum potassium more than 5/5 mmol/l
• heart failure (NYHA III-IV)
• congenital heart disease
• acute coronary syndrome less than 3 months before enrollment